Raising Capital for AML cancer Biotech startup

Title: Strategic Capital Formation Lead (Contract, Part-Time to Start) Company: Bifrost Medicines, LLC Location: Flexible / Remote Type: Contract; part-time initially, with engagement expected through the close of a Series A and potential to expand thereafter About Bifrost Medicines Bifrost Medicines is building a rare precision oncology company around a genetically defined AML program with the potential to become a highly differentiated therapeutic asset. Our lead effort is centered on inv(16) AML, a molecularly defined subtype with strong biological rationale and no approved targeted therapy specifically directed at the core driver complex. We are working around science associated with Dr. John Bushweller and a small-molecule program designed to directly interfere with the leukemogenic RUNX1–CBFβ-SMMHC interaction. We believe this creates a particularly compelling genotype-to-mechanism-to-therapy story in a setting where specificity, patient definition, and mechanistic clarity matter. We are now seeking a capital formation leader to help us raise financing and build the right long-term investor base around the company. This is a contract role and will begin on a part-time basis. The immediate objective is to help the company prepare for and execute a successful Series A financing process. For the right person, the role could expand over time, but the initial mandate is clear: help us raise capital intelligently, efficiently, and with the right strategic partners around the table. This is not a generic fundraising role. We are looking for someone with a real network, real judgment, and real experience raising capital in biotech, ideally in rare disease, oncology, precision oncology, or genetically defined therapeutic programs. The right person will understand that the investors most likely to back a company like this are not simply “biotech investors,” but a narrower set of people who understand early mechanistic science, differentiated oncology company formation, and the value of highly defined patient populations. Role Overview This person will lead or co-lead the company’s capital formation effort and serve as a key strategic partner to the founders on a contract basis. The role is focused on helping Bifrost secure the right financing partners to advance the company from its current stage toward a larger institutional syndicate and a successful Series A raise. The successful candidate will know how to translate a deeply scientific rare precision oncology story into a fundraising process that resonates with venture capital firms, crossover investors, family offices with biotech experience, strategic investors, and other specialized healthcare capital sources. They will be able to identify who is actually relevant, get the company in front of those people, shape the narrative, manage the process, and help close the financing. This is a high-trust, high-impact role. We are not looking for someone to compile a generic investor spreadsheet or spray out cold outreach. We are looking for someone who already has an existing network and can credibly open doors with investors who matter in rare precision oncology and early-stage biotech. What You Will Do You will develop and drive the company’s fundraising strategy, including target investor mapping, financing process design, outreach sequencing, and message calibration. You will help refine how the company is positioned to investors, including how we frame the scientific thesis, the competitive landscape, the unmet need in inv(16) AML, the company-building opportunity, and the rationale for why this is a precision oncology company rather than simply an early AML project. You will identify, prioritize, and activate the investors, company builders, and strategic relationships most likely to understand the value of a genetically defined oncology asset at this stage. You will make warm introductions where you have them, create opportunities where you do not, and help build a process that feels disciplined, targeted, and credible. You will work closely with the founders on deck development, data presentation, diligence preparation, investor follow-up, and process management. You will help shape financing strategy across multiple possible pathways, including seed-extension, pre-Series A, Series A, tranched financings, strategic capital, foundation-connected capital, and other specialized structures appropriate for an early rare precision oncology company. You will also help assess investor quality, not just investor interest. We care deeply about bringing in the right people around the table. This means understanding which firms truly know oncology, which ones understand highly targeted genetic subtypes, which ones can support company formation, and which ones are unlikely to be helpful despite name recognition. Who You Are You have meaningful experience raising capital in biotech, therapeutics, life sciences, or healthcare. You have a real and current network of investors, strategic counterparties, and company builders. Ideally, that network includes individuals or firms who have backed precision oncology, rare disease, targeted oncology, genetically selected programs, or hematologic malignancy companies. You understand the difference between broad oncology and rare precision oncology. You know why certain investors are drawn to clean genotype-to-therapy stories and why others are not. You have a feel for who will appreciate early mechanistic science, who will want more mature packages, and who can be engaged now versus later. You are commercially sophisticated but scientifically credible. You do not need to be a scientist, but you do need to be able to understand and communicate complex biology in a way that is accurate, disciplined, and compelling. You should be comfortable operating in a founder-led environment where the science is real, the opportunity is differentiated, and the company is still being built. You are proactive, organized, and unusually good at moving a process forward without creating noise. You know how to manage investor conversations, maintain momentum, track next steps, and keep founders focused on the highest-value opportunities. You know how to get meetings, and you know how to convert meetings into a process. Strong candidates may come from biotech business development, investor relations, venture capital, specialized banking, healthcare fundraising, or founder-adjacent strategic roles. Prior direct experience raising capital for rare precision oncology companies is highly attractive. What Success Looks Like Success in this role means helping Bifrost build a focused and credible investor process around its lead rare precision oncology asset. It means refining the message, getting the company in front of the right people, creating momentum with serious investors, and helping the company close a strong Series A financing with partners who understand both the science and the strategic opportunity. This role is especially well suited for someone who wants to work closely with founders, help shape a financing narrative from the ground up, and play a meaningful role in the formation of a new rare precision oncology company. Compensation Compensation will be structured for a contract, part-time role initially and for solely for stock options until our Series A closes. After closing, it can include a mix of cash and success-based economics. We are open to discussing a structure that appropriately aligns incentives through the close of the Series A. How to Express Interest Please reach out with a brief description of your background, your experience raising capital in biotech, and any relevant history in rare disease, oncology, precision oncology, or genetically defined therapeutics. We are especially interested in candidates who already have trusted relationships with investors active in early-stage precision oncology and company formation.